文献速递泌尿男性生殖肿瘤

VHL缺失驱动透明细胞肾细胞癌增强子激活致癌基因

VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.
PubMed 文献 · Cancer Discov · 2017-09-11

该研究分析10对原发肿瘤/正常配对和9个细胞系的79个染色质图谱,发现ccRCC中增强子广泛功能异常。VHL缺失主要导致增强子/超级增强子失调,HIF2α-HIF1β异二聚体结合增强子并招募p300,超级增强子分析鉴定ZNF395为ccRCC特异性且VHL调控的主调控因子,其耗竭在体外和体内几乎完全消除肿瘤。

要点

  • ccRCC中增强子功能广泛异常,相关靶基因与组织特异性恶性特征相关。
  • VHL缺失主要驱动增强子/超级增强子失调,而非启动子,并在ccRCC标志基因附近获得活性增强子标记。
  • ZNF395被鉴定为ccRCC特异性且VHL调控的主调控因子,其耗竭在体外和体内几乎完全消除肿瘤。

核心结论

  • VHL缺失通过稳定HIF2α-HIF1β异二聚体结合增强子并招募p300,驱动增强子功能异常和致癌基因表达,ZNF395为ccRCC主调控因子。

研究设计与样本

  • 分析10对原发肿瘤/正常配对和9个细胞系的79个染色质图谱。

主要发现

  • ccRCC中增强子广泛功能异常,相关增强子靶基因与组织特异性恶性特征相关。
  • 超级增强子分析鉴定ZNF395为ccRCC特异性且VHL调控的主调控因子,其耗竭在体外和体内几乎完全消除肿瘤。
  • VHL缺失主要驱动增强子/超级增强子失调而非启动子,并在ccRCC标志基因附近获得活性增强子标记(H3K27ac、H3K4me1)。
  • VHL缺失稳定HIF2α-HIF1β异二聚体结合增强子,招募组蛋白乙酰转移酶p300,而不明显影响既有启动子-增强子相互作用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel-Lindau (VHL) tumor suppressor. Roles for noncoding cis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal pairs and 9 cell lines across 79 chromatin profiles, we observed pervasive enhancer malfunction in ccRCC, with cognate enhancer-target genes associated with tissue-specific aspects of malignancy. Superenhancer profiling identified ZNF395 as a ccRCC-specific and VHL-regulated master regulator whose depletion causes near-complete tumor elimination in vitro and in vivoVHL loss predominantly drives enhancer/superenhancer deregulation more so than promoters, with acquisition of active enhancer marks (H3K27ac, H3K4me1) near ccRCC hallmark genes. Mechanistically, VHL loss stabilizes HIF2α-HIF1β heterodimer binding at enhancers, subsequently recruiting histone acetyltransferase p300 without overtly affecting preexisting promoter-enhancer interactions. Subtype-specific driver mutations such as VHL may thus propagate unique pathogenic dependencies in ccRCC by modulating epigenomic landscapes and cancer gene expression.Significance: Comprehensive epigenomic profiling of ccRCC establishes a compendium of somatically altered cis-regulatory elements, uncovering new potential targets including ZNF395, a ccRCC master regulator. Loss of VHL, a ccRCC signature event, causes pervasive enhancer malfunction, with binding of enhancer-centric HIF2α and recruitment of histone acetyltransferase p300 at preexisting lineage-specific promoter-enhancer complexes. Cancer Discov; 7(11); 1284-305. ©2017 AACR.See related commentary by Ricketts and Linehan, p. 1221This article is highlighted in the In This Issue feature, p. 1201.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Yao X, Tan J, Lim KJ, et al. VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. Cancer Discov. 2017. PMID: 28893800. doi:10.1158/2159-8290.CD-17-0375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。